SEC Form 4 · accession 0001562180-16-002300
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Dinarello
Director
Period of report
May 9, 2016
Accepted (ET)
May 10, 2016 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 9, 2016 | S | 5,000 | $101.91 | D | 6,559 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $91.78 | holding | — | — | — | Oct 30, 2014 | Oct 30, 2024 | Common Stock | 4,000 | 4,000 | D |
| Stock Options (Right to Buy) | $87.39 | holding | — | — | — | Oct 31, 2013 | Oct 30, 2023 | Common Stock | 4,000 | 4,000 | D |
| Stock Options (Right to Buy) | $87.34 | holding | — | — | — | Oct 29, 2016 | Oct 28, 2025 | Common Stock | 4,260 | 4,260 | D |
| Stock Options (Right to Buy) | $70.35 | holding | — | — | — | Oct 27, 2011 | Oct 26, 2021 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to Buy) | $66.90 | holding | — | — | — | Oct 25, 2012 | Oct 24, 2022 | CommonS tock | 5,000 | 5,000 | D |
| Stock Options (Right to Buy) | $66.59 | holding | — | — | — | Oct 25, 2007 | Oct 24, 2017 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to Buy) | $65.47 | holding | — | — | — | Oct 23, 2008 | Oct 22, 2018 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to Buy) | $63.03 | holding | — | — | — | Oct 29, 2009 | Oct 28, 2019 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to Buy) | $61.46 | holding | — | — | — | Oct 28, 2010 | Oct 27, 2020 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.85 to $102.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.